# CURRENT_OPERATIONAL.md — Knee-OA post-review amendment closeout

> **STATUS:** KNEE-OA POST-REVIEW BOUNDED AMENDMENT — IMPLEMENTED / FOCUSED TECHNICAL GATE PASS / PRODUCT-OWNER VISUAL REVIEW NEXT.
> **Updated:** 2026-09-12 Asia/Nicosia.
> **Canonical home:** `athpapachr-cmd/osteoporosis`.
> **Freshly verified `main`:** `d9f312f6d2d596ec0bd4f35f6de56ad98dc34b37`.
> **Previously accepted reviewed candidate:** `6539351c592c1dc3e49931057b63925dea3cb94d`.
> **Synthesis/disposition parent:** `554ecfa30bf8d0c04a19510a5db0276e6844edd5`.
> **Implementation branch:** `feat/physio-knee-oa-review-amendments-v1-2026-09-12`.
> **Closed slice:** `CU1-PRODUCT-KNEE-OA-POST-REVIEW-AMENDMENTS-V1-20260912`.
> **Tested substantive amendment head:** `83a5acd4e5b25413708bbda1715c58b5c78bce08`.
> **Result record:** `clinic_utilities/physio_referral_product/KNEE_OA_POST_REVIEW_AMENDMENT_RESULT_V1.md`.
> **ACTIVE RUNTIME / DESIGN / CANONICAL WRITER:** NONE; amendment writer released.
> **PR / merge / deploy / production smoke authority:** NONE.
> **Real-patient use / production integration:** NOT AUTHORIZED.

## 1. Product result

The post-review synthetic candidate now implements the approved bounded corrections without expanding the clinical surface indiscriminately.

Implemented:

- explicit Knee-OA diagnosis selection acts as clinician assertion and auto-projects diagnosis; the checkbox-like confirmation presentation is removed from the intended UX;
- exact local missing-state guidance for diagnosis then laterality;
- generic weakness remains reported/contextual, while quadriceps-specific canonical weakness requires explicit examination semantics;
- FFD remains advanced/optional and is expressed as passive extension deficit, distinct from active lag, with no numeric `0°` or permanence wording;
- no new main-activity / functional-baseline structured field was added;
- low-information referrals are proportionally shorter;
- richer plan prose is framed as physiotherapy assessment plus indicative priorities rather than a fixed technique/dose/progression order;
- qualifier visible/ARIA lifecycle is synchronized while multi-location pain selection remains possible;
- routine evidence first disclosure is lighter, while mixed guidance still shows all material source positions immediately;
- suggestion presentation is flatter without weakening Add/evidence/dismissal/stale-candidate guards;
- mobile manual reconciliation is more direct;
- a visible `CY_GESY` / `Κύπρος · ΓεΣΥ` jurisdiction context seam is present without importing unaudited local recommendations.

## 2. General utility rule retained

```text
clinically meaningful
!= workflow-useful
!= receiver-useful
!= worth adding
```

Product Owner, author, assistant and reviewer suggestions remain hypotheses until the relevant utility/evidence/receiver gate supports them.

## 3. Exact gate evidence

First run `34672583682` failed because an inherited regression still required amended product prose to be byte-for-byte identical to frozen Step-3 output. The test ownership was corrected rather than deleting frozen protection.

Successful substantive run:

```text
workflow                                  Physio Knee OA prototype gate
run                                       34672654522
head                                      83a5acd4e5b25413708bbda1715c58b5c78bce08
result                                    SUCCESS
real CU-1 / HTTP tests                    15 / 15 PASS
frozen Step-3 exact-output fixtures       15 PASS
post-review clinical/output tests         11 / 11 PASS
inherited Chromium tests                  12 / 12 PASS
post-review Chromium tests                 9 / 9 PASS
Greek source-summary coverage             54 positions
packaged dependency closure               PASS
scope + syntax guards                     PASS
```

The successful run produced a runnable synthetic ZIP plus desktop/mobile/conflict-evidence screenshots.

## 4. Jurisdiction architecture boundary

The intended reusable model is:

```text
international clinical-evidence core
+
optional jurisdiction/local-system guidance overlay
```

The current `CY_GESY` label is context only. It cannot change evidence states, defaults, suggestions or copied clinical prose until the exact final Cyprus/HIO recommendation content is audited and separately authorized.

Future `GR` or `UK_ENGLAND` profiles remain dormant until actual market/workflow need is established. Country must later come from explicit configuration/account preference, not silent device-location inference.

## 5. Remaining acceptance

Still unproven:

```text
Product Owner visual/use acceptance of this amended candidate
actual receiving-physiotherapist user validation
actual iPhone Safari / VoiceOver
complete measured contrast/accessibility acceptance
Cyprus/GeSY recommendation-by-recommendation audit
production privacy/auth/hosting
Greece/England market need
commercial willingness-to-pay / retention
```

## 6. Exact next action

**Product Owner visually/use-tests the exact tested synthetic amendment artifact.** Record concrete keep/remove/change findings only after interacting with this candidate.

No second diagnosis, jurisdiction expansion, PR, merge, deploy or production integration follows automatically from the technical PASS.
